Nuvation Bio will present updated long-term Phase 2 results and three ongoing trial overviews for safusidenib, a selective inhibitor targeting mutant IDH1 in glioma patients, at the Society for Neuro-Oncology Annual Meeting in November 2026. The updated data expands on positive topline results announced earlier in July, highlighting safusidenib's potential for durable responses in IDH1-mutant glioma, a brain cancer affecting mostly younger adults. These presentations underscore the progress in developing targeted therapies for this cancer type, with further Phase 3 studies underway. The company aims to advance treatment options for patients with limited current therapies.
Nuvation Bio shares trade at USD 4.76 on Pluang as of Nov 02, 2026 20:13 WIB, down 0.21% for the day. The stock's market cap stands at $1.67 billion, with a 52-week range between $4.05 and $9.54. Typical holding time on Pluang is 17 days, reflecting moderate investor interest amid ongoing clinical updates.
